StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
5592.T$2537.00-1.28%
Fair $2537.00+0.0%

5592.T

Kusurinomadoguchi, Inc.

Healthcare / Health Information ServicesTokyo

$2537.00

-33.00 (-1.28%)

Fairly Valued+0.0%Fair Value $2537.00Fund rank 32/100 · Data gapFallback financials|
SA 58/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $999.2M · quality 55.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 34/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 5592.TLocal privado en este navegador · Kusurinomadoguchi, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$29.1B

P/E

9.8x

↓

EV/EBITDA

8.9x

↓

ROE

24.1%

↑

Gross Margin

57.8%

↑

Debt/Equity

0.01

↓
52-Week Range$2537
$2362$4685

TradingView lightweight chart

5592.T price, volumen y niveles de valoración

Último $2,537Periodo +57.6%
Fair value: $2,537

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+19.9%

FCF CAGR

—

FCF margin

-63.7%

FCF / Net income

-3.50x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $11.20B · net income $2.03B · FCF $-7.13B

2022-FY → 2025-FY

Gross margin

57.8%+5.9% pts

Operating margin

17.4%+6.4% pts

Net margin

18.2%+10.2% pts

FCF margin

-63.7%-103.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$11.20B$11.20B$8.72B$7.42B$6.49B
Net Income$2.03B$2.03B$870.9M$391.5M$515.6M
EBITDA$2.97B$2.97B$2.35B$1.68B$1.51B
EPS180.63180.6384.0042.6447.39
Gross Margin57.8%57.8%56.6%54.9%52.0%
Operating Margin17.4%17.4%15.7%14.1%11.0%
Net Margin18.2%18.2%10.0%5.3%7.9%
Balance Sheet
Debt/Equity0.010.010.850.05—
Current Ratio1.941.94———
Cash Flow
Free Cash Flow$-7.13B$-7.13B$999.2M$1.57B$2.58B
Returns
ROE24.1%24.1%13.7%14.5%21.0%
Valuation
P/E9.779.7716.58——
EV/EBITDA8.948.942.24——
P/B3.383.382.27——
Growth & Yield
Revenue Growth28.4%28.4%17.5%14.4%—
EPS Growth115.0%115.0%97.0%-10.0%—
Dividend Yield1.6%1.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

7.6%

razonable

EPS terminal req.

$225.12

Spread vs growth

107.4%

5Y implied EPS CAGR

8.6%

razonable

EPS terminal req.

$272.39

Spread vs growth

106.5%

10Y implied EPS CAGR

9.3%

razonable

EPS terminal req.

$438.69

Spread vs growth

105.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +5.7%

Total return

+5.7%

Start / end P/E

29.0x → 14.0x

EPS bridge

84.00 → 180.63

Residual

-59.3%

EPS growth+115.0%
Multiple rerating-51.5%
Dividend+1.6%
Residual / FX / buybacks / cross-term-59.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.